NCT04410653View on ClinicalTrials.gov

Afatinib in Advanced NRG1-Rearranged Malignancies

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 31, 2022

Primary Completion Date

October 4, 2023

Study Completion Date

October 4, 2023

Conditions
Metastatic and Locally Advanced NRG1-rearranged Malignancies
Interventions
DRUG

Afatinib 40 MG

single oral dose of afatinib each day starting at a dose of 40 mg on day 1, continuously, until the development of progressive disease or unacceptable adverse events

Trial Locations (2)

69120

NCT Heidelberg, Heidelberg

01307

NCT Dresden, Dresden

All Listed Sponsors
collaborator

German Consortium for Translational Cancer Research

OTHER

lead

German Cancer Research Center

OTHER